NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Up 21.0% in June

NewAmsterdam Pharma (NASDAQ:NAMSW) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 12,100 shares, an increase of 21.0% from the May 31st total of 10,000 shares. Based on an average daily volume of 5,500 shares, the days-to-cover ratio is currently 2.2 days.

Institutional Investors Weigh In On NewAmsterdam Pharma

A hedge fund recently raised its stake in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC grew its holdings in NewAmsterdam Pharma (NASDAQ:NAMSW) by 47.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 202,599 shares of the company’s stock after acquiring an additional 65,599 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $2,237,000 at the end of the most recent reporting period.

NewAmsterdam Pharma Price Performance

NASDAQ NAMSW traded up $1.39 during trading hours on Tuesday, hitting $10.40. 8,765 shares of the company were exchanged, compared to its average volume of 12,671. The company has a 50 day moving average of $9.22 and a two-hundred day moving average of $8.69. NewAmsterdam Pharma has a 52-week low of $0.99 and a 52-week high of $14.67.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.